Cardiomyopathy Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
Retrospective part (using existing records):
- Children under 18 years old at the time they were enrolled or at the time of death, for whom medical data is available.
- People who have genetic test results showing at least one harmful or likely harmful change (mutation) in a gene called MYBPC3 — this includes having one copy of the mutation, two copies, or two different mutations in that gene.
Prospective part (going forward):
- Babies who have two copies of a known harmful MYBPC3 gene mutation (either two of the same, or two different ones that both affect the gene).
- Children under 18 years old at the time of joining the prospective part of the study, with genetic test results confirming at least one harmful or likely harmful MYBPC3 mutation, and who have been diagnosed with a type of heart muscle disease (such as thickened heart muscle, enlarged heart muscle, stiff heart muscle, or a mixed or spongy-heart-muscle condition).
Who may not be able to join:
Retrospective part:
- Patients who received a heart transplant or died more than 10 years before the study started — though exceptions may apply for babies with two copies of the MYBPC3 mutation (confirm with trial site).
Prospective part:
- People who are currently taking part in another clinical trial that involves a treatment or intervention, unless the organisation running this trial gives approval.
- People who have a serious non-heart-related illness that is expected to significantly shorten their life expectancy.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Phone: 650-209-8092
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
To characterize the disease course and natural history in participants with pathogenic or likely pathogenic MYBPC3 mutations with a specific focus on cardiac events and measurement
Can't join this trial?
Data last synced from ClinicalTrials.gov: 26 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.